Search

Your search keyword '"Cortelazzo S"' showing total 421 results

Search Constraints

Start Over You searched for: Author "Cortelazzo S" Remove constraint Author: "Cortelazzo S"
421 results on '"Cortelazzo S"'

Search Results

2. P1245: CLINICAL IMPACT OF IMMUNOGLOBULIN HEAVY CHAIN REPERTOIRE IN MANTLE CELL LYMPHOMA: A STUDY FROM THE FONDAZIONE ITALIANA LINFOMI (FIL) PHASE III MCL0208 TRIAL.

4. Early-stage diffuse large B cell lymphoma of the head and neck: clinico-biological characterization and 18 year follow-up of 488 patients (IELSG 23 study)

8. A COMPLETELY GENETIC PROGNOSTIC MODEL OVERCOMES CLINICAL PROGNOSTICATORS IN MANTLE CELL LYMPHOMA: RESULTS FROM THE MCL0208 TRIAL FROM THE FONDAZIONE ITALIANA LINFOMI (FIL)

11. The CIBMTR score predicts survival of AML patients undergoing allogeneic transplantation with active disease after a myeloablative or reduced intensity conditioning: a retrospective analysis of the Gruppo Italiano Trapianto Di Midollo Osseo

16. Clofarabine and Treosulfan as Conditioning for Matched Related and Unrelated Hematopoietic Stem Cell Transplantation: Results from the Clo3o Phase II Trial

17. Anthracycline-based chemotherapy as primary treatment for intravascular lymphoma

19. Patterns of Outcome and Prognostic Factors in Primary Large-Cell Lymphoma of the Testis in a Survey by the International Extranodal Lymphoma Study Group

21. COMPREHENSIVE ANALYSIS OF BASELINE OUTCOME BIOPREDICTORS IN YOUNGER PATIENTS WITH MANTLE CELL LYMPHOMA: THE ANCILLARY BIOLOGICAL STUDIES OF FONDAZIONE ITALIANA LINFOMI (FIL) MCL0208 CLINICAL TRIAL

22. PROGNOSTIC VALUE OF CLONAL HEMATOPOIESIS-MUTATIONS DETECTED AT DIAGNOSIS IN ACUTE MYELOID LEUKEMIA PATIENTS WITH NORMAL KARYOTYPE

23. PF227 PROGNOSTIC VALUE OF CLONAL HEMATOPOIESIS-MUTATIONS DETECTED AT DIAGNOSIS IN ACUTE MYELOID LEUKEMIA PATIENTS WITH NORMAL KARYOTYPE

24. PS1312 QPCR, MFC AND DDPCR: COMPARISON ON MRD SAMPLES FROM THREE PROSPECTIVE TRIALS OF THE EUROPEAN MCL NETWORK

25. PS1248 COMPREHENSIVE ANALYSIS OF BASELINE OUTCOME BIOPREDICTORS IN YOUNGER PATIENTS WITH MANTLE CELL LYMPHOMA: THE ANCILLARY BIOLOGICAL STUDIES OF FONDAZIONE ITALIANA LINFOMI (FIL) MCL0208 CLINICAL TRIAL

26. MOLECULAR PROLIFE BY NEXT GENERATION SEQUENCING OF ACUTE MYELOID LEUKEMIA WITH NORMAL KARYOTYPE: CLINICAL RESULTS FROM THE PROSPECTIVE TRIAL 02/06 OF THE NORTHERN ITALY LEUKEMIA GROUP (NILG)

29. Role of radiotherapy in patients with early-stage diffuse large B-cell lymphoma of Waldeyer's ring in remission after anthracycline-containing chemotherapy

30. KMT2D AND TP53 MUTATIONS PREDICT POOR PFS AND OS IN MANTLE CELL LYMPHOMA RECEIVING HIGH-DOSE THERAPY AND ASCT: THE FONDAZIONE ITALIANA LINFOMI (FIL) MCL0208 PHASE III TRIAL

31. NOVEL MOLECULAR MARKERS FOR MINIMAL RESIDUAL DISEASE (MRD) MONITORING IN MANTLE CELL AND FOLLICULAR LYMPHOMA: THE TARGETED LOCUS AMPLIFICATION (TLA) NGS STRATEGY

32. Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma

33. CLIPI: a new prognostic index for indolent cutaneous B cell lymphoma proposed by the International Extranodal Lymphoma Study Group (IELSG 11)

34. High response rate and improvement of long-term survival with combined treatment modalities in patients with poor-risk primary thyroid diffuse large B-cell lymphoma: an International Extranodal Lymphoma Study Group and Intergruppo Italiano Linfomi study

35. Relevance of intraocular involvement in the management of primary central nervous system lymphomas

36. Treosulfan-fludarabine-ATG-F based reduced-toxicity conditioning regimen: multicentre 'Allo-Treo' study, results in 183 patients with haematological malignancies

37. Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy following autologous hematopoietic stem-cell transplantation in patients with newly diagnosed multiple myeloma

39. High-dose sequential chemoimmunotherapy supported by autologous stem cell transplantation in patients with systemic B-cell lymphoma and central nervous system involvement: interim analysis of a multicentre phase II Trial

40. Factors influencing the occurrence of secondary malignancies in high-risk lymphoma patients following high-dose therapy and autograft

41. Allogeneic Stem Cell Transplantation (Allo-SCT) Following a Reduced-Intensity Conditioning (RIC) Regimen in Relapsed Peripheral T-Cell Lymphomas (PTCL): Results at 4 Year of Median Follow-up

42. ANTRACYCLINE BASED CHEMOTHERAPY AS PRIMARY TREATMENT FOR INTRAVASCULAR LYMPHOMA

43. TIME OF PERIPHERAL BLOOD PROGENITOR CELL COLLECTIONS MAY INFLUENCE THE RISK OF SECONDARY MYELODYSPLASTIC SYNDROME/ACUTE LEUKEMIA FOLLOWING INTENSIVE THERAPY AND AUTOGRAFT: A GITIL SURVEY ON 1,347 LYMPHOMA PATIENTS RECEIVING THE HIGH-DOSE SEQUENTIAL PROGRAM

44. Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage

45. Update of a GITIL cohort study: Frontline high dose sequential chemotherapy with rituximab and autologous stem cell transplantation induces a high rate of long-term remissions in patients with mantle cell lymphoma

46. The risk of secondary myelodysplastic syndrome/acute leukemia following intensive therapy and autograft correlates with the type of cells grafted: A survey on 1,347 lymphoma patients receiving the high-dose sequential (HDS) program

47. Impact of complete remission achievement on the survival of lymphoma patients undergoing high-dose sequential chemotherapy and autograft (HDS programme): a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) retrospective study on 1,266 patients

48. Incidence and risk factors of secondary myelodysplastic syndromelacute leukemia occurrence following peripheral blood progenitor cell autograft: a GITIL (Gruppo Italiano Terapie Innovative Nei Linfomi) survey on 1266 lymphoma patients

49. Rituximab markedly improves the efficacy of high-dose programmes with autograft for B-cell lymphoma: a multicentre GITIL survey on 957 patients

Catalog

Books, media, physical & digital resources